Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 4 clients • 10 examiners • 7 art units • 0 of 10 (0%) have an AI response strategy ready
White & Case LLP handles patent prosecution in the Biotechnology & Pharmaceuticals technology area, with 2801 career applications on record. The firm has a resolved allowance rate of 81.01 percent. Its prosecution history shows an average of 2.65 office actions per allowance. Currently, the firm is managing 7 pending office actions.
The 2801 career applications and 81.01 percent allowance rate establish the firm's historical performance in this sector. The 2.65 average helps practitioners understand the typical procedural requirements for reaching an allowance. With 7 pending office actions, the firm maintains its presence in Biotechnology & Pharmaceuticals. This data set reflects the firm's documented experience and current workload within the patent office. The recorded metrics provide a baseline for procedural duration in this specific field. Practitioners can evaluate the intensity of examiner interaction and resource requirements based on these historical figures. These statistics offer a view of the firm's prosecution profile.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (20%) |
| §112 only | 2 (20%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 4 (40%) |
| Multi-statute (no §101) | 1 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, SIN J | 1 | 68.8% | +25.1% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| SZPERKA, MICHAEL EDWARD | 1 | 62.9% | +36.8% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
| PATEL, SAGAR S | 1 | 75.7% | +34.6% |
| BAEK, JONGHWAN NMN | 1 | 60.0% | +0.0% |
| D' AMBROSIO, THEA | 1 | 55.3% | +56.1% |
| MIKNIS, ZACHARY J | 1 | 68.6% | +32.2% |
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | RYAN, DOUGLAS CHARLES | 60d overdue |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | MIKNIS, ZACHARY J | 21d |
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | LEE, SIN J | — |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | CHANDRA, GYAN | — |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | SZPERKA, MICHAEL EDWARD | — |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | STOICA, ELLY GERALD | — |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | PATEL, SAGAR S | — |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | D' AMBROSIO, THEA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Acceleron Pharma | 5 |
| Xylonix Pte. Ltd. | 2 |
| Disc Medicine | 2 |
| Encoded Therapeutics | 1 |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1618 | 1 |
| 1654 | 1 |
| 1658 | 1 |
| 1635 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18797689 | GAMMA-POLYGLUTAMIC ACID AND ZINC COMPOSITIONS | Xylonix Pte. Ltd. | LEE, SIN J | 1613 | §103 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18443985 | METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS | Acceleron Pharma, Inc. | CHANDRA, GYAN | DP | Non-Final OA | — | Pending | Feb 16, 2024 | |
| 18683894 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | Acceleron Pharma, Inc. | SZPERKA, MICHAEL EDWARD | §102§103DP | Non-Final OA | — | Pending | Feb 15, 2024 | |
| 18580425 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | STOICA, ELLY GERALD | §112 | Non-Final OA | — | Pending | Jan 18, 2024 | |
| 18562510 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Disc Medicine, Inc. | NOLAN, JASON MICHAEL | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18290403 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS | Disc Medicine, Inc. | PATEL, SAGAR S | 1626 | §103§112DPOther | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18282094 | PHARMACEUTICAL POLYMER CONJUGATES | Xylonix Pte. Ltd. | BAEK, JONGHWAN NMN | 1618 | §103§112DP | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18280899 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma, Inc. | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Acceleron Pharma, Inc. | MIKNIS, ZACHARY J | 1658 | §112 | Non-Final OA | 21d | Pending | Dec 19, 2022 |
| 17442057 | MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS | Encoded Therapeutics, Inc. | RYAN, DOUGLAS CHARLES | 1635 | §103 | Non-Final OA | 60d overdue | Pending | Sep 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial